Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript

May 13, 2026 / 08:30 PM GMT

Release Date Price: MXN25.5 (-0.20%)

Transcript 8-K10-Q

Key Points

Positve

Inovio Pharmaceuticals Inc (INO) is advancing its lead candidate, INO-3107, through the regulatory process with a target PDUFA date of October 30, 2026.
The FDA completed a mid-cycle review of INO-3107 with no new significant issues raised, indicating positive progress in the approval process.
Inovio Pharmaceuticals Inc (INO) has strengthened its balance sheet with a public equity offering, extending its cash runway into the first quarter of 2027.
The company is actively preparing for the commercial launch of INO-3107, including engaging commercial partners and completing product positioning work.
Inovio Pharmaceuticals Inc (INO) is leveraging partnerships to advance other promising candidates in its pipeline, including collaborations for glioblastoma treatment and next-generation DNA medicine platforms.

Negative

The FDA has yet to schedule an informal meeting to discuss INO-3107's eligibility for accelerated approval, which could delay the approval process.
Inovio Pharmaceuticals Inc (INO) reported a net loss of $19.7 million for the first quarter of 2026, indicating ongoing financial challenges.
The company's cash reserves decreased from $58.5 million at the end of 2025 to $37.7 million in the first quarter of 2026, highlighting financial strain.
There is uncertainty regarding the impact of the FDA commissioner's resignation on the review timeline for INO-3107.
Inovio Pharmaceuticals Inc (INO) faces competition from existing products like the gorilla adenoviral-based immunotherapy, which may impact market penetration and acceptance of INO-3107.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INO.OQ - Inovio Pharmaceuticals Inc
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call
May 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and welcome to the Innovio First Quarter 2026 Financial Results Conference Call.

At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 13th, 2026.

I would now like to turn the conference over to Jenny Wilson. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.